Fierce Drug Dev Forum 2019 has ended
avatar for Dr. Josep Bassaganya-Riera

Dr. Josep Bassaganya-Riera

Chairman and CEO
Dr. Josep Bassaganya-Riera, Chairman and CEO of Landos Biopharma, is an innovator, serial entrepreneur & thought leader in biotech. He has published over 200 peer-reviewed publications & patents and has founded 3 award-winning companies, raising over $125 million in non-dilutive and equity financing rounds. By harnessing the power of advanced computational modeling and AI in combination with preclinical, translational and clinical R&D, Landos BioPharma is more efficiently developing and revealing the true value of new oral drugs for autoimmune diseases including its lead candidate, BT-11 expected to begin Phase 2 testing for UC and CD. Landos has leveraged advanced computational algorithms to screen potential new drugs and simulate clinical trials. Through a combination of advanced computational modeling, informatics, and immunology experimentation, plus using alternative financial models and agile management approaches, Landos has created a deep pipeline of candidates for diseases such as IBD, UC, CD, Lupus, RA and others.  Josep was named 2017 Innovator of the Year & received the 2018 Biocomplexity Research Excellence Award.